Article Sidebar

Submitted
May 17, 2021
Published
May 17, 2021
Download
PDF
Statistic
Read Counter : 47 Download : 50

Main Article Content

Abstract

Carbapenems are a group of β-lactam antimicrobial agents with an exceptionally broad spectrum of activity. They are used as a last resort against many multi drug resistant, gram negative bacteria, and in cases of infections due to extended spectrum beta lactamase (ESBL) and Amp C enzyme producing Enterobacteriaceae. CRE, which stands for carbapenem-resistant Enterobacteriaceae, are a family of germs that are difficult to treat because they have high levels of resistance to antibiotics. However, widespread and irrational use of carbapenems has led to emergence of resistance to this group of drugs also, and there are at present very few available antibiotics, which are active against carbapenem-resistant (CR) organisms. Infections with CR organisms are associated with high morbidity and mortality with the attributable mortality rate as high as 40-50%. Carbapenem resistance is a global concern and the presence of CR genes in Indian subcontinent and its potential of international spread have been reported previously. Pharmacists have a responsibility to assist in the war on antibiotic resistance. They have the knowledge and resources at their fingertips to raise awareness and to act. There are multiple opportunities for pharmacists to assist in this campaign. The recognition of pharmacists as key members of antibiotic stewardship teams in health systems is a milestone in infectious-diseases pharmacy practice.

Keywords

Extended spectrum beta lactamase Carbapenem resistant enterobacteriaceae Carbapenem resistant genes Antibiotic stewardship Multi drug resistance

Article Details

How to Cite
V Hrishi, J Keerthy, B H Sagarika, K Sattanathan, & N Venkateswara Murthy. (2021). A review on carbapenem resistance and the role of pharmacist in antibiotic stewardship programmes in India. International Journal of Research in Pharmacology & Pharmacotherapeutics, 5(1), 76-81. https://doi.org/10.61096/ijrpp.v5.iss1.2016.76-81
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin. Microbiol. Infect.18 (5), 439–448(2012).
  2. [2]. Petrosillo N, Capone A, Di Bella S, Taglietti F. Management of antibiotic resistance in the intensive care unit setting. Expert Rev. Anti. Infect. Ther.8 (3), 289–302(2010).
  3. [3]. Rahal JJ. Antimicrobial resistance among and therapeutic options against Gram-negative pathogens. Clin. Infect. Dis.49, S4–S10(2009).
  4. [4]. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit. Care Med. 38(8), 1651–1664(2010).
  5. [5]. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-negative bacteria. Clin. Microbiol. Rev. 25(3), 450–470(2012).
  6. [6]. Queenan AM, Bush K. Carbapenemases: the versatile β- Lac¬tamases. Clinical Microbiology Reviews 2007; 20:440-458.
  7. [7]. Nagaraj S, Chandran SP, Shamanna P, Macaden R. Car¬bapenem resistance among Escherichia coli and Klebsiella pneumoniaeae in a tertiary care hospital in south India. In¬dian J Med Microbiol 2012; 30:93-95.
  8. [8]. Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007;122 (2):160–166.
  9. [9]. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
  10. [10]. Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.Int J Antimicrob Agents. 2005;25(1):11–25.
  11. [11]. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006; 355(7):666–674.
  12. [12]. Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007; 56(14):332–336.